FDA's new Guidance Documents for 2012
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The U.S. Food and Drug Administration FDA has issued its yearly list of planned draft and final guidance documents for 2012. There are about 50 such guidance documents planned.
This is an overview about some important ones:
Biopharmaceutics and Biosimilarity:
- Scientific Considerations in Demonstrating Biosimilarity To a Reference Product
- Quality Considerations in Demonstrating Biosimilarity To a Reference Protein Product
Combination Products:
- Development of Drugs in Combination
cGMPs and Compliance:
- Control of Highly Potent Compounds
- Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
Labeling, Packaging and Supply Chain:
- Securing the Drug Supply Chain-Standards for Tracking and Tracing Prescription Drug Packages
- Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling
Source: FDA Guidance Agenda
Compiled by
Wolfgang Schmitt
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
19.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
14.01.2026New Ph. Eur. Publication Schedule
07.01.2026Is QP Certification required when Products do not enter EU Territory?
17.12.2025EU Reaches Landmark on Reform of Pharmaceutical Legislation